Literature DB >> 18829747

Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.

Joe Grove1, Søren Nielsen, Jin Zhong, Margaret F Bassendine, Heidi E Drummer, Peter Balfe, Jane A McKeating.   

Abstract

Hepatitis C virus (HCV) infection is dependent on at least three coreceptors: CD81, scavenger receptor BI (SR-BI), and claudin-1. The mechanism of how these molecules coordinate HCV entry is unknown. In this study we demonstrate that a cell culture-adapted JFH-1 mutant, with an amino acid change in E2 at position 451 (G451R), has a reduced dependency on SR-BI. This altered receptor dependency is accompanied by an increased sensitivity to neutralization by soluble CD81 and enhanced binding of recombinant E2 to cell surface-expressed and soluble CD81. Fractionation of HCV by density gradient centrifugation allows the analysis of particle-lipoprotein associations. The cell culture-adapted mutation alters the relationship between particle density and infectivity, with the peak infectivity occurring at higher density than the parental virus. No association was observed between particle density and SR-BI or CD81 coreceptor dependence. JFH-1 G451R is highly sensitive to neutralization by gp-specific antibodies, suggesting increased epitope exposure at the virion surface. Finally, an association was observed between JFH-1 particle density and sensitivity to neutralizing antibodies (NAbs), suggesting that lipoprotein association reduces the sensitivity of particles to NAbs. In summary, mutation of E2 at position 451 alters the relationship between particle density and infectivity, disrupts coreceptor dependence, and increases virion sensitivity to receptor mimics and NAbs. Our data suggest that a balanced interplay between HCV particles, lipoprotein components, and viral receptors allows the evasion of host immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829747      PMCID: PMC2593310          DOI: 10.1128/JVI.01569-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  80 in total

1.  Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant.

Authors:  Artur Kaul; Ilka Woerz; Philip Meuleman; Geert Leroux-Roels; Ralf Bartenschlager
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

2.  Effect of cell polarization on hepatitis C virus entry.

Authors:  Christopher J Mee; Joe Grove; Helen J Harris; Ke Hu; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

3.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.

Authors:  Mirjam B Zeisel; George Koutsoudakis; Eva K Schnober; Anita Haberstroh; Hubert E Blum; François-Loïc Cosset; Takaji Wakita; Daniel Jaeck; Michel Doffoel; Cathy Royer; Eric Soulier; Evelyne Schvoerer; Catherine Schuster; Françoise Stoll-Keller; Ralf Bartenschlager; Thomas Pietschmann; Heidi Barth; Thomas F Baumert
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

4.  The lipid droplet is an important organelle for hepatitis C virus production.

Authors:  Yusuke Miyanari; Kimie Atsuzawa; Nobuteru Usuda; Koichi Watashi; Takayuki Hishiki; Margarita Zayas; Ralf Bartenschlager; Takaji Wakita; Makoto Hijikata; Kunitada Shimotohno
Journal:  Nat Cell Biol       Date:  2007-08-26       Impact factor: 28.824

5.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

6.  Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.

Authors:  Sonia Molina; Valerie Castet; Lydiane Pichard-Garcia; Czeslaw Wychowski; Eliane Meurs; Jean-Marc Pascussi; Camille Sureau; Jean-Michel Fabre; Antonio Sacunha; Dominique Larrey; Jean Dubuisson; Joliette Coste; Jane McKeating; Patrick Maurel; Chantal Fournier-Wirth
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

7.  Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.

Authors:  Jennifer M Timpe; Zania Stamataki; Adam Jennings; Ke Hu; Michelle J Farquhar; Helen J Harris; Anne Schwarz; Isabelle Desombere; Geert Leroux Roels; Peter Balfe; Jane A McKeating
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.

Authors:  Ursula Andréo; Patrick Maillard; Olga Kalinina; Marine Walic; Eliane Meurs; Michèle Martinot; Patrick Marcellin; Agata Budkowska
Journal:  Cell Microbiol       Date:  2007-05-21       Impact factor: 3.715

9.  High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.

Authors:  Maria Teresa Catanese; Rita Graziani; Thomas von Hahn; Martine Moreau; Thierry Huby; Giacomo Paonessa; Claudia Santini; Alessandra Luzzago; Charles M Rice; Riccardo Cortese; Alessandra Vitelli; Alfredo Nicosia
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

10.  Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.

Authors:  Catherine A Blish; Minh-An Nguyen; Julie Overbaugh
Journal:  PLoS Med       Date:  2008-01-03       Impact factor: 11.069

View more
  80 in total

1.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

2.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Authors:  Haihong Zhu; Flossie Wong-Staal; Haekyung Lee; Andrew Syder; Jeffrey McKelvy; Robert T Schooley; David L Wyles
Journal:  J Infect Dis       Date:  2012-02-15       Impact factor: 5.226

3.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.

Authors:  Huahao Fan; Luhua Qiao; Kyung-Don Kang; Junfen Fan; Wensheng Wei; Guangxiang Luo
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

4.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

5.  Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.

Authors:  Fang Chen; Yinglan Zhao; Min Liu; Dongqing Li; Hongyan Wu; Haidan Chen; Yongzhe Zhu; Fengling Luo; Jin Zhong; Yidan Zhou; Zhongtian Qi; Xiao-Lian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

6.  A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Authors:  Adam Zuiani; Kevin Chen; Megan C Schwarz; James P White; Vincent C Luca; Daved H Fremont; David Wang; Matthew J Evans; Michael S Diamond
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

7.  New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Authors:  Lucie Fénéant; Julie Potel; Catherine François; Famara Sané; Florian Douam; Sandrine Belouzard; Noémie Calland; Thibaut Vausselin; Yves Rouillé; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Dimitri Lavillette; Didier Hober; Jean Dubuisson; Czeslaw Wychowski; Laurence Cocquerel
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

8.  Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Authors:  Mark S Sulkowski; Minhee Kang; Roy Matining; David Wyles; Victoria A Johnson; Gene D Morse; Valerianna Amorosa; Debika Bhattacharya; Kristine Coughlin; Flossie Wong-Staal; Marshall J Glesby
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

9.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 10.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.